Lycopene in Healthy Male Participants
Launched by NATIONAL CANCER INSTITUTE (NCI) · Mar 20, 2007
Trial Information
Current as of June 08, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES:
I. Compare the toxicity and safety of 2 different doses of oral lycopene in healthy male participants.
II. Compare the pharmacokinetics of 2 different doses of this drug in these participants.
III. Determine the toxicity and pharmacokinetics needed to proceed to a large phase II/III study in men at high risk for prostate cancer.
OUTLINE: This is a randomized, crossover study. Participants are randomized to 1 of 2 treatment arms.
Arm I: Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossove...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy volunteers judged to be in good medical condition based on history and physical exam
- • Karnofsky performance status 100%
- • AST and ALT ≤ 75 IU/L
- • Bilirubin ≤ 2.0 mg/dL
- • Creatinine ≤ 1.5 mg/dL
- • Hemoglobin ≥ 13.0 g/dL
- • WBC ≥ 4,000/mm³
- • Platelet count ≥ 150,000/mm³ and ≤ 400,000/mm³
- • Must be within height and weight standards identified by Metropolitan Life scales
- • Nonsmoker (for ≥ 3 months)
- • No history of alcohol abuse
- • No history of gastrointestinal malabsorption or other condition that could affect drug absorption
- • No history of a psychiatric condition
- • No chronic medical condition
- * No active history of any of the following:
- • Cancer
- • Liver disease
- • Cardiovascular disease
- • Renal disease
- • Diabetes mellitus
- • Other illnesses that, in the opinion of the investigator, could represent a threat for the participants life
- • No allergy to tomato-based products
- • No lycopene in the diet for ≥ 14 days
- • At least 4 weeks since prior and no other concurrent experimental medications
- • No concurrent participation in another experimental study
- • No concurrent use of regular prescription medication or over-the-counter medications
- • No concurrent vitamin, mineral, or herbal supplements
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Keith Rodvold
Principal Investigator
University of Illinois at Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials